Compare Medpace Holdings Inc (MEDP) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Ryanair Holdings plc — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Ryanair Holdings plc trades at $59.4 (market cap $29.63B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.51% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | RYAAY | |
|---|---|---|
Market Cap | $16.90B | $29.63B |
Sector | Technology | Industrials |
52-Week High | $620.59 | $73.82 |
52-Week Low | $393.42 | $53.24 |
Enterprise Value | $16.52B | $26.61B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
RYAAY trades at $59.36, down 0.25% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and attractive valuation with a P/E of 14.37. Recent news highlights a strategic AI partnership with Google Cloud and industry challenges from lower fares and fuel costs.
The outlook is balanced; analyst consensus is bullish (62.5% buy ratings), but near-term headwinds from fare pressure and geopolitical risks persist. The stock offers value based on earnings, though operational volatility and competitive dynamics require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
